Company profile
Psyence Group Inc.
OTC: PSYGF · Healthcare · Drug Manufacturers - General
Canadian filerHQ Toronto, ONReports USD
#1161 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 24
v0.1 · 5/100 weight · pillars only
↑ balance-sheet leverage, return on assets · ↓ listing tenure, Altman-Z
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$287.7k
Employees
—
as of 2026-08-25
Market cap
$2.2M
as of 2026-08-25
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$00 CAD2025
Net income-$287.7k-400.2k CAD2025
Operating income-$4.0M-5.5M CAD2025
Total assets$7.4M10.6M CAD2025
Liabilities$739.9k1.1M CAD2025
Equity$895.4k1.3M CAD2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Psyence Group Inc.’s revenue?
Psyence Group Inc. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Indo Global Exchange(s) PTE, Ltd.——BioVaxys Technology Corp.——VitaSpring Biomedical Co. Ltd.18DLifeline Biotechnologies, Inc.——Nu-Med Plus, Inc.23DGenprex, Inc.34DKey facts
CEOJody Aufrichtig
SectorHealthcare
IndustryDrug Manufacturers - General
HeadquartersToronto, ON
ExchangeOTC: PSYGF
Employees—
IPO date2022-05-31
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.